Immuron Limited (IMRN): Price and Financial Metrics

Immuron Limited (IMRN)

Today's Latest Price: $6.75 USD

0.27 (-3.85%)

Updated Oct 30 4:00pm

Add IMRN to Watchlist
Sign Up

Overall POWR Rating

POWR Components:

 Trade Grade  Buy & Hold Grade  Peer Grade  Industry Rank

Industry Rank:

Ranked of 240 in Medical - Pharmaceuticals

See all "A" rated Strong Buy stocks

IMRN Stock Summary

  • The ratio of debt to operating expenses for Immuron Ltd is higher than it is for about merely 0.37% of US stocks.
  • With a year-over-year growth in debt of -100%, Immuron Ltd's debt growth rate surpasses just 0% of about US stocks.
  • The volatility of Immuron Ltd's share price is greater than that of 96.54% US stocks with at least 200 days of trading history.
  • If you're looking for stocks that are quantitatively similar to Immuron Ltd, a group of peers worth examining would be GENC, GIGM, ELSE, FEIM, and NSSC.
  • IMRN's SEC filings can be seen here. And to visit Immuron Ltd's official web site, go to

IMRN Stock Price Chart Interactive Chart >

Price chart for IMRN

IMRN Price/Volume Stats

Current price $6.75 52-week high $28.99
Prev. close $7.02 52-week low $1.55
Day low $6.65 Volume 24,700
Day high $7.11 Avg. volume 1,121,532
50-day MA $7.86 Dividend yield N/A
200-day MA $5.75 Market Cap 37.81M

Immuron Limited (IMRN) Company Bio

Immuron Limited focuses on developing and commercializing oral immunotherapeutics for the treatment of various gut medicated diseases in Australia and internationally. The company operates through Research and Development, and HyperImmune Products segments. The company was founded in 1994 and is based in Australia.

IMRN Latest News Stream

Event/Time News Detail
Loading, please wait...

IMRN Latest Social Stream

Loading social stream, please wait...

View Full IMRN Social Stream

Latest IMRN News From Around the Web

Below are the latest news stories about Immuron Ltd that investors may wish to consider to help them evaluate IMRN as an investment opportunity.

Immuron Limited Announces Closing of $20.0 Million Registered Direct Offering

MELBOURNE, Australia, July 23, 2020 (GLOBE NEWSWIRE) -- Immuron Limited (ASX: IMC; NASDAQ: IMRN), (the “Company”), an Australian biopharmaceutical company focused on developing and commercializing oral immunotherapeutics for the prevention and treatment of gut mediated pathogens, today announced the closing of its previously announced registered direct offering of 1,066,668 American Depositary Shares (“ADSs”), each representing forty (40) of the Company’s ordinary shares, at a purchase price of $18.75 per ADS for gross proceeds of approximately US$20.0 million. H.C. Wainwright & Co. acted as the exclusive placement agent for the offering.The Company intends to use the net proceeds from this offering to fund Immuron’s research and development, preclinical and clinical programs, support ...

Yahoo | July 23, 2020

70 Biggest Movers From Yesterday

Gainers Midatech Pharma PLC-ADR (NASDAQ: MTP ) shares climbed 152.9% to close at $4.30 on Tuesday after the company announced a research collaboration for the Q-Sphera platform with a European pharmaceutical company. Owens & Minor, Inc. (NYSE: OMI ) rose 81.4% to close at $14.40 after the company announced preliminary results for the second quarter. Owens & Minor sees preliminary Q2 adjusted EPS of $0.18-$0.20. Novan, Inc. (NASDAQ: NOVN ) shares jumped 78.3% to close at $1.23 on Tuesday after climbing 12% on Monday. Immuron Limited (NASDAQ: IMRN ) shares gained 42.3% to close at $14.81 after the company said its IMM-124E — used to manufacture its flagship commercially available and over-the-counter gastrointestinal and digestive health immune supplements Travelan and Protectyn — has dem...

Benzinga Feeds | July 22, 2020

Introducing Immuron (ASX:IMC), The Stock That Soared 387% In The Last Year

While stock picking isn't easy, for those willing to persist and learn, it is possible to buy shares in great...

Yahoo | July 22, 2020

45 Stocks Moving in Tuesday's Pre-Market Session

Gainers Immuron Limited (NASDAQ: IMRN) shares rose 97.9% to $20.60 in pre-market trading after the company reported neutralizing activity against …

Benzinga | July 21, 2020

Why Nanocap Biotech Immuron's Stock Is On A 2-Day Run

Shares of Australian biopharma IMMURON LTD/S ADR (NASDAQ: IMRN ) were rallying for the second day in a row Tuesday following an announcement concerning a potential COVID-19 treatment option. Immuron's Coronavirus Development: Immuron's IMM-124E has demonstrated neutralizing activity against SARS-CoV-2, the virus that causes COVID-19, according to the company. The technology platform offers a potential new oral therapeutic approach to target SARS-CoV-2 in the gastrointestinal tract, Immuron said. IMM-124E is an oral polyclonal antibody therapy used to manufacture the biopharma's commercially available over-the-counter gastrointestinal and digestive heath immune supplements Travelan and Protectyn. It is also being evaluated in other indications such as NASH. The in-vitro assessment of the...

Benzinga | July 21, 2020

Read More 'IMRN' Stories Here

IMRN Price Returns

1-mo -10.00%
3-mo -32.57%
6-mo 180.08%
1-year 103.15%
3-year 29.06%
5-year N/A
YTD 85.95%
2019 N/A
2018 0.00%
2017 N/A
2016 N/A
2015 N/A

Continue Researching IMRN

Want to see what other sources are saying about Immuron Ltd's financials and stock price? Try the links below:

Immuron Ltd (IMRN) Stock Price | Nasdaq
Immuron Ltd (IMRN) Stock Quote, History and News - Yahoo Finance
Immuron Ltd (IMRN) Stock Price and Basic Information | MarketWatch

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from!

Page generated in 0.6367 seconds.